This content is machine translated Disease-modifying therapies for ATTR-CM TTR stabilizers, gene silencing and gene scissors: where do we stand? Advances in the understanding of the pathophysiology of transthyretin amyloid cardiomyopathy (ATTR-CM) have revolutionized the therapeutic landscape in recent years. TTR stabilizers such as tafamidis and acoramidis can reduce TTR...…
